Find your next quality investment with Simply Wall St’s straightforward and powerful screener, trusted by over 7 million individual investors worldwide.
Agilent Technologies (A) has drawn fresh attention after launching its S540MD Slide Scanner System in key European markets, a digital pathology scanner that utilizes AI-assisted tissue detection to support high-throughput clinical workflows.
See our latest analysis for Agilent Technologies.
The new S540MD launch comes as Agilent’s recent share price performance has been under pressure, with a 90 day share price return of an 8.77% decline and a 1 year total shareholder return of a 10.10% decline, suggesting momentum has been fading even as product news and upcoming earnings keep the story active.
If this kind of health focutilized AI adoption catches your eye, it may be worth scanning the wider opportunity set across healthcare stocks.
With Agilent’s share price under pressure despite new products and analysts’ higher price tarobtains, the key question is whether recent weakness leaves the stock undervalued or if the market is already accounting for future growth.
Agilent Technologies’ most followed valuation story puts fair value at $168.59 a share, comfortably above the recent $135.05 close. That gap all comes from detailed growth and margin assumptions built into a discounted cash flow model utilizing a 7.94% discount rate.
Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.
Want to see what kind of revenue mix, margin lift, and future earnings multiple are necessaryed to support that valuation gap? The most followed narrative lays out a tight set of growth, profitability, and share count assumptions that all have to line up for $168.59 to build sense.
Result: Fair Value of $168.59 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this upbeat story could be knocked off course if tariff driven cost pressures weigh on margins, or if key pharma and advanced materials replacement cycles slow.
Find out about the key risks to this Agilent Technologies narrative.
That 19.9% undervaluation story sits uneasily next to what the market is paying today. Agilent trades on a P/E of 29.4x, which is below global Life Sciences peers at 37.7x and a peer group average of 33.6x, yet still above a fair ratio of 23.8x that our model suggests the market could relocate toward. In plain terms, even if shares view cheaper than many rivals, there is valuation risk if sentiment cools and the multiple drifts closer to that fair ratio.
Leave a Reply